PharmaCyte Biotech (PMCB) Total Non-Current Liabilities (2015 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Total Non-Current Liabilities of $826424.0 for Q2 2026, down 71.64% year-over-year from $2.9 million in Q2 2025, and down 50.76% quarter-over-quarter from $1.7 million in Q1 2026.
PharmaCyte Biotech (PMCB) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Total Non-Current Liabilities for 5 consecutive years, with $826424.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 71.64% year-over-year to $826424.0; the TTM figure through Apr 2026 stood at $826424.0 (down 71.64% YoY), while the FY2026 annual figure was $826424.0, down 71.64% from the prior year.
- Total Non-Current Liabilities slipped to $826424.0 in Q2 2026 per PMCB's latest filing, from $1.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.6 million in Q2 2024 and bottomed at $586581.0 in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $4.0 million across 4 years, with a median of $3.3 million in 2025.
- Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 1537.5% — and 2025, when it tumbled 87.45%.
- PharmaCyte Biotech's Total Non-Current Liabilities stood at $5.2 million in 2023, then dropped by 8.84% to $4.8 million in 2024, then sank by 31.53% to $3.3 million in 2025, then tumbled by 74.73% to $826424.0 in 2026.
- Business Quant data shows PMCB's Total Non-Current Liabilities at $826424.0 in Q2 2026, $1.7 million in Q1 2026, and $3.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.54 Bn | 130.69 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.89 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.65 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.53 Bn | 51.39 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | 826,424.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 826,424.00 |
| Jan 31, 2026 | 1.68 Mn |
| Oct 31, 2025 | 3.27 Mn |
| Jul 31, 2025 | 1.06 Mn |
| Apr 30, 2025 | 2.91 Mn |
| Jan 31, 2025 | 1.19 Mn |
| Oct 31, 2024 | 4.78 Mn |
| Jul 31, 2024 | 8.45 Mn |
| Apr 30, 2024 | 9.61 Mn |
| Jan 31, 2024 | 7.54 Mn |
| Oct 31, 2023 | 5.24 Mn |
| Jul 31, 2023 | 4.82 Mn |
| Apr 30, 2023 | 586,581.00 |
| Oct 31, 2015 | 1.05 Mn |
| Apr 30, 2015 | 1.03 Mn |